Cover Image
市場調查報告書

非小細胞肺癌 (NSCLC):市場分析、預測 ∼2035年

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035

出版商 Datamonitor Healthcare 商品編碼 498962
出版日期 內容資訊 英文 549 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
非小細胞肺癌 (NSCLC):市場分析、預測 ∼2035年 Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035
出版日期: 2017年03月19日 內容資訊: 英文 549 Pages
簡介

本報告提供非小細胞肺癌 (NSCLC)的已上市藥物及開發平台趨勢調查,疾病概要,年齡、男女的發病率,目前治療選擇,主要藥物的銷售額及投藥患者數的變化與預測,已上市藥物簡介,開發平台趨勢等彙整資料。

NSCLC市場預測:美國、日本、歐盟5國

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、調查手法
  • Abemaciclib
  • Abraxane (白蛋白結合Paclitaxel)
  • Alecensa (Alectinib)
  • Alimta (Pemetrexed)
  • Atezolizumab
  • Avastin (Bevacizumab)
  • Avelumab
  • AZD9291
  • Brigatinib
  • Cyramza (Ramucirumab)
  • Durvalumab
  • Ganetespib
  • Gilotrif (Afatinib)
  • Iressa (Gefitinib)
  • Keytruda (Pembrolizumab)
  • Necitumumab
  • Opdivo (Nivolumab)
  • Rociletinib
  • Selumetinib
  • Tarceva (Erlotinib)
  • TG4010
  • Tremelimumab
  • Vargatef (Nintedanib)
  • Veliparib
  • Xalkori (Crizotinib)
  • Yervoy (Ipilimumab)
  • Zykadia (Ceritinib)

NSCLC的治療:美國、日本、歐盟5國

  • 摘要整理
  • 主要調查手法
  • 疾病定義、診斷
  • 患者區分
  • 目前治療選擇

NSCLC的流行病學:美國、日本、歐盟5國

  • 摘要整理
  • 疾病定義
  • 全球變化
  • 風險要素
  • 資訊來源、調查手法
  • 預測
  • 流行病學者的見解
  • 優勢、規定
  • 文獻

已上市藥物:非小細胞肺癌

  • 摘要整理
  • 產品概要
  • 產品簡介:Alecensa
  • 產品簡介:Alimta
  • 產品簡介:Avastin
  • 產品簡介:Cyramza
  • 產品簡介:Gilotrif
  • 產品簡介:Iressa
  • 產品簡介:Keytruda
  • 產品簡介:Opdivo
  • 產品簡介:Portrazza
  • 產品簡介:Tagrisso
  • 產品簡介:Tarceva
  • 產品簡介:Vargatef
  • 產品簡介:Xalkori
  • 產品簡介:Zykadia

開發平台:非小細胞肺癌

  • 摘要整理
  • 臨床實驗平台:概要
  • 臨床試驗設計
  • 近幾年開發中止的藥物
  • 產品簡介 (開發後期):ASP8273
  • 產品簡介 (開發後期):Lucanix
  • 產品簡介 (開發後期):Tecentriq
  • 產品簡介 (開發後期):Abemaciclib
  • 產品簡介 (開發後期):Avelumab
  • 產品簡介 (開發後期):Brigatinib
  • 產品簡介 (開發後期):Dacomitinib
  • 產品簡介 (開發後期):Durvalumab
  • 產品簡介 (開發後期):ensartinib
  • 產品簡介 (開發後期):Napabucasin
  • 產品簡介 (開發後期):Veliparib

圖表

目錄
Product Code: DMKC5724

Disease Overview

Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending on the country in question. The main types of NSCLC are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLC presents significant public health problems for nearly every country, largely due to the fact that diagnosis generally happens in the advanced stages, and there is a high death rate associated with the disease. The future of NSCLC treatment will reflect the era of personalized therapies as mutation status becomes one of the main determinants of treatment choice.

TABLE OF CONTENTS

FORECAST: NON-SMALL CELL LUNG CANCER IN THE US, JAPAN, AND 5EU

  • Executive Summary
  • Market Overview and Trends
  • Market Definition and Methodology
  • abemaciclib
  • Abraxane (albumin-bound paclitaxel)
  • Alecensa (alectinib)
  • Alimta (pemetrexed)
  • atezolizumab
  • Avastin (bevacizumab)
  • avelumab
  • AZD9291
  • brigatinib
  • Cyramza (ramucirumab)
  • durvalumab
  • ganetespib
  • Gilotrif (afatinib)
  • Iressa (gefitinib)
  • Keytruda (pembrolizumab)
  • necitumumab
  • Opdivo (nivolumab)
  • rociletinib
  • selumetinib
  • Tarceva (erlotinib)
  • TG4010
  • tremelimumab
  • Vargatef (nintedanib)
  • veliparib
  • Xalkori (crizotinib)
  • Yervoy (ipilimumab)
  • Zykadia (ceritinib)

TREATMENT: NON-SMALL CELL LUNG CANCER IN THE US, JAPAN, AND 5EU

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Patient Segmentation
  • Current Treatment Options

EPIDEMIOLOGY: NON-SMALL CELL LUNG CANCER IN THE US, JAPAN, AND 5EU

  • Executive Summary
  • Disease Definition
  • Global Variation
  • Risk Factors
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations
  • Bibliography

MARKETED DRUGS: NON-SMALL CELL LUNG CANCER

  • Executive Summary
  • Product Overview
  • Product profile: Alecensa
  • Product profile: Alimta
  • Product profile: Avastin
  • Product profile: Cyramza
  • Product profile: Gilotrif
  • Product profile: Iressa
  • Product profile: Keytruda
  • Product profile: Opdivo
  • Product profile: Portrazza
  • Product profile: Tagrisso
  • Product profile: Tarceva
  • Product profile: Vargatef
  • Product profile: Xalkori
  • Product profile: Zykadia

PIPELINE: NON-SMALL CELL LUNG CANCER

  • Executive Summary
  • Clinical Pipeline Overview
  • Clinical Trial Design
  • Recently Discontinued Drugs
  • Product profile (late stage): ASP8273
  • Product profile (late stage): Lucanix
  • Product profile (late stage): Tecentriq
  • Product profile (late stage): abemaciclib
  • Product profile (late stage): avelumab
  • Product profile (late stage): brigatinib
  • Product profile (late stage): dacomitinib
  • Product profile (late stage): durvalumab
  • Product profile (late stage): ensartinib
  • Product profile (late stage): napabucasin
  • Product profile (late stage): veliparib

List of figures

  • Figure 1: Non-small cell lung cancer market value in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 2: Non-small cell lung cancer market value in the US, Japan, and five major EU markets, by drug class ($m), 2014-23
  • Figure 3: Sales of PD-1/PD-L1 inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
  • Figure 4: Sales of EGFR inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
  • Figure 5: Sales of ALK inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
  • Figure 6: Patient-based forecast methodology for non-small cell lung cancer
  • Figure 7: Abemaciclib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 8: Abraxane sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 9: Alecensa sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 10: Alimta sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 11: Atezolizumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 12: Avastin sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 13: Avelumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 14: AZD9291 sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 15: Brigatinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 16: Cyramza sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 17: Durvalumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 18: Ganetespib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 19: Gilotrif sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 20: Iressa sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 21: Keytruda sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 22: Necitumumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 23: Opdivo sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 24: Rociletinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 25: Selumetinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 26: Tarceva sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 27: TG4010 sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 28: Tremelimumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 29: Vargatef sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 30: Veliparib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 31: Xalkori sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 32: Yervoy sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 33: Zykadia sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 34: Histological division of Stage IIIb-IV NSCLC patients in the US, Japan, and five major EU markets
  • Figure 35: Distribution of NSCLC patients by stage of disease across the US, Japan, and five major EU markets
  • Figure 36: Top three therapeutic strategies used in the treatment of Stage Ia-IIIa NSCLC across the US, Japan, and five major EU markets, by stage
  • Figure 37: Uptake of surgical and non-surgical treatment modalities for patients with Stage IIIa NSCLC
  • Figure 38: Uptake of neoadjuvant and adjuvant chemotherapy in patients with Stage IIIa NSCLC whose treatment includes both surgery and chemotherapy
  • Figure 39: Top three chemotherapy regimens used in the adjuvant treatment of Stage IIIa NSCLC in the US, Japan, and five major EU markets, by country
  • Figure 40: Top three chemotherapy regimens used in the neoadjuvant treatment of Stage IIIa NSCLC in the US, Japan, and five major EU markets, by country
  • Figure 41: Top three therapeutic strategies used in the treatment of Stage IIIb NSCLC across the US, Japan, and five major EU markets, by country
  • Figure 42: Top three therapeutic strategies used in the treatment of Stage IV NSCLC in the US, Japan, and five major EU markets, by country
  • Figure 43: Top three chemotherapy regimens used in the first-line treatment of Stage IV NSCLC in the US, Japan, and five major EU markets, by country
  • Figure 44: Usage of Avastin (in any combination) in first-line chemotherapy regimens for Stage IV NSCLC in the US, Japan, and five major EU markets, by country
  • Figure 45: Percentage of Stage IIIb-IV non-squamous NSCLC patients who are tested for each mutation in the US, Japan, and five major EU markets, by country
  • Figure 46: Percentage of Stage IIIb-IV squamous NSCLC patients who are tested for each mutation in the US, Japan, and five major EU markets, by country
  • Figure 47: Uptake of EGFR inhibitors as first-line chemotherapies for Stage IV NSCLC patients in the US, Japan, and five major EU markets, by country
  • Figure 48: Uptake of Xalkori as a first-line chemotherapy for Stage IV NSCLC patients in the US, Japan, and five major EU markets, by country
  • Figure 49: Use of maintenance therapy in Stage IIIb and Stage IV NSCLC patients in the US, Japan, and five major EU markets, by country
  • Figure 50: Top three maintenance therapies used in Stage IIIb and Stage IV NSCLC in the US, Japan, and five major EU markets, by country
  • Figure 51: Percentage of Stage IV NSCLC patients who receive second-line treatment with chemotherapy and/or chemoradiation, by country
  • Figure 52: Top three chemotherapy and/or chemoradiation regimens used in the second-line treatment of Stage IV NSCLC, by country
  • Figure 53: Percentage of second-line Stage IV NSCLC patients who receive third-line treatment with chemotherapy and/or chemoradiation, by country
  • Figure 54: Top three chemotherapy and/or chemoradiation regimens used in the third-line treatment of Stage IV NSCLC, by country
  • Figure 55: Percentage of Stage I-IIIb NSCLC patients who relapse with local and distant disease in theUS, Japan, and five major EU markets, by country
  • Figure 56: Top three therapeutic strategies used in the treatment of Stage I-IIIb NSCLC patients who relapse with local disease, by country
  • Figure 57: Top three therapeutic strategies used in the treatment of Stage I-IIIb NSCLC patients who relapse with distant disease, by country
  • Figure 58: Top three chemotherapy regimens used in the first-line treatment of Stage I-IIIb NSCLC patients who relapse with distant disease, by country
  • Figure 59: Top chemotherapy/chemoradiation regimens used in the second-line treatment of Stage I-IIIbSCLC patients who relapse with distant disease
  • Figure 60: Top three chemotherapy/chemoradiation regimens used in the third-line treatment of Stage I-IIIb NSCLC patients who relapse with distant disease
  • Figure 61: Age-standardized Incidence rates of lung cancer (all types), 2012
  • Figure 62: Age-specific incidence rates of lung cancer (all types) among men, 2012
  • Figure 63: Age-specific incidence rates of lung cancer (all types) among women, 2012
  • Figure 64: Age-standardized lung cancer (all types) incidence rates among men, 1993-2007
  • Figure 65: Age-standardized lung cancer (all types) incidence rates among women, 1993-2007
  • Figure 66: Age-standardized lung cancer (all types) mortality rates, 2010
  • Figure 67: Age-specific mortality rates of lung cancer (all types) among men, 2010
  • Figure 68: Age-specific mortality rates of lung cancer (all types) among women, 2010
  • Figure 69: Age-standardized lung cancer (all types) mortality rates among men, 1980-2010
  • Figure 70: Age-standardized lung cancer (all types) mortality rates among women, 1980-2010
  • Figure 71: Trend in incident cases of lung cancer (all types) in the US, Japan, and five major EU markets, 2013-33
  • Figure 72: Trend in incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, 2013-33
  • Figure 73: Absolute growth in incident cases of non-small cell lung cancer in the US, Japan, and five najor EU markets, 2013-33
  • Figure 74: Age-specific trends in incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, 2013-33
  • Figure 75: Age-standardized incidence of non-small cell lung cancer in the US, Japan, and five major EU markets, by sex and market, 2013
  • Figure 76: Alecensa for non-small cell lung cancer - SWOT analysis
  • Figure 77: Datamonitor Healthcare's drug assessment summary for Alecensa in non-small cell lung cancer
  • Figure 78: Datamonitor Healthcare's drug assessment summary for Alecensa in non-small cell lung cancer
  • Figure 79: Alimta for non-small cell lung cancer - SWOT analysis
  • Figure 80: Datamonitor Healthcare's drug assessment summary for Alimta in non-small cell lung cancer
  • Figure 81: Datamonitor Healthcare's drug assessment summary for Alimta in non-small cell lung cancer
  • Figure 82: Avastin for non-small cell lung cancer - SWOT analysis
  • Figure 83: Datamonitor Healthcare's drug assessment summary for Avastin in non-small cell lung cancer
  • Figure 84: Datamonitor Healthcare's drug assessment summary for Avastin in non-small cell lung cancer
  • Figure 85: Cyramza for non-small cell lung cancer - SWOT analysis
  • Figure 86: Datamonitor Healthcare's drug assessment summary for Cyramza in non-small cell lung cancer
  • Figure 87: Datamonitor Healthcare's drug assessment summary for Cyramza in non-small cell lung cancer
  • Figure 88: Gilotrif for non-small cell lung cancer - SWOT analysis
  • Figure 89: Datamonitor Healthcare's drug assessment summary for Gilotrif in non-small cell lung cancer
  • Figure 90: Datamonitor Healthcare's drug assessment summary for Gilotrif in non-small cell lung cancer
  • Figure 91: Iressa for non-small cell lung cancer - SWOT analysis
  • Figure 92: Datamonitor Healthcare's drug assessment summary for Iressa in non-small cell lung cancer
  • Figure 93: Datamonitor Healthcare's drug assessment summary for Iressa in non-small cell lung cancer
  • Figure 94: Keytruda for non-small cell lung cancer - SWOT analysis
  • Figure 95: Datamonitor Healthcare's drug assessment summary for Keytruda in non-small cell lung cancer
  • Figure 96: Datamonitor Healthcare's drug assessment summary for Keytruda in non-small cell lung cancer
  • Figure 97: Opdivo for non-small cell lung cancer - SWOT analysis
  • Figure 98: Datamonitor Healthcare's drug assessment summary for Opdivo in non-small cell lung cancer
  • Figure 99: Datamonitor Healthcare's drug assessment summary for Opdivo in non-small cell lung cancer
  • Figure 100: Portrazza for non-small cell lung cancer - SWOT analysis
  • Figure 101: Datamonitor Healthcare's drug assessment summary for Portrazza in non-small cell lung cancer
  • Figure 102: Datamonitor Healthcare's drug assessment summary for Portrazza in non-small cell lung cancer
  • Figure 103: Tagrisso for non-small cell lung cancer - SWOT analysis
  • Figure 104: Datamonitor Healthcare's drug assessment summary for Tagrisso in non-small cell lung cancer
  • Figure 105: Datamonitor Healthcare's drug assessment summary for Tagrisso in non-small cell lung cancer
  • Figure 106: Tarceva for non-small cell lung cancer - SWOT analysis
  • Figure 107: Datamonitor Healthcare's drug assessment summary for Tarceva in non-small cell lung cancer
  • Figure 108: Datamonitor Healthcare's drug assessment summary for Tarceva in non-small cell lung cancer
  • Figure 109: Vargatef for non-small cell lung cancer - SWOT analysis
  • Figure 110: Datamonitor Healthcare's drug assessment summary for Vargatef in non-small cell lung cancer
  • Figure 111: Datamonitor Healthcare's drug assessment summary for Vargatef in non-small cell lung cancer
  • Figure 112: Xalkori for non-small cell lung cancer - SWOT analysis
  • Figure 113: Datamonitor Healthcare's drug assessment summary for Xalkori in non-small cell lung cancer
  • Figure 114: Datamonitor Healthcare's drug assessment summary for Xalkori in non-small cell lung cancer
  • Figure 115: Zykadia for non-small cell lung cancer - SWOT analysis
  • Figure 116: Datamonitor Healthcare's drug assessment summary for Zykadia in non-small cell lung cancer
  • Figure 117: Datamonitor Healthcare's drug assessment summary for Zykadia in non-small cell lung cancer
  • Figure 118: ASP8273 for non-small cell lung cancer - SWOT analysis
  • Figure 119: Datamonitor Healthcare's drug assessment summary for ASP8273 in non-small cell lung cancer
  • Figure 120: Datamonitor Healthcare's drug assessment summary for ASP8273 in non-small cell lung cancer
  • Figure 121: Lucanix for non-small cell lung cancer - SWOT analysis
  • Figure 122: Datamonitor Healthcare's drug assessment summary for Lucanix in non-small cell lung cancer
  • Figure 123: Datamonitor Healthcare's drug assessment summary for Lucanix in non-small cell lung cancer
  • Figure 124: Tecentriq for non-small cell lung cancer - SWOT analysis
  • Figure 125: Datamonitor Healthcare's drug assessment summary for Tecentriq in non-small cell lung cancer
  • Figure 126: Datamonitor Healthcare's drug assessment summary for Tecentriq in non-small cell lung cancer
  • Figure 127: Abemaciclib for non-small cell lung cancer - SWOT analysis
  • Figure 128: Datamonitor Healthcare's drug assessment summary for abemaciclib in non-small cell lung cancer
  • Figure 129: Datamonitor Healthcare's drug assessment summary for abemaciclib in non-small cell lung cancer
  • Figure 130: Avelumab for non-small cell lung cancer - SWOT analysis
  • Figure 131: Datamonitor Healthcare's drug assessment summary for avelumab in non-small cell lung cancer
  • Figure 132: Datamonitor Healthcare's drug assessment summary for avelumab in non-small cell lung cancer
  • Figure 133: Brigatinib for non-small cell lung cancer - SWOT analysis
  • Figure 134: Datamonitor Healthcare's drug assessment summary for brigatinib in non-small cell lung cancer
  • Figure 135: Datamonitor Healthcare's drug assessment summary for brigatinib in non-small cell lung cancer
  • Figure 136: Dacomitinib for non-small cell lung cancer - SWOT analysis
  • Figure 137: Datamonitor Healthcare's drug assessment summary for dacomitinib in non-small cell lung cancer
  • Figure 138: Datamonitor Healthcare's drug assessment summary for dacomitinib in non-small cell lung cancer
  • Figure 139: Durvalumab for non-small cell lung cancer - SWOT analysis
  • Figure 140: Datamonitor Healthcare's drug assessment summary for durvalumab in non-small cell lung cancer
  • Figure 141: Datamonitor Healthcare's drug assessment summary for durvalumab in non-small cell lung cancer
  • Figure 142: Ensartinib for non-small cell lung cancer - SWOT analysis
  • Figure 143: Datamonitor Healthcare's drug assessment summary for ensartinib in non-small cell lung cancer
  • Figure 144: Datamonitor Healthcare's drug assessment summary for ensartinib in non-small cell lung cancer
  • Figure 145: Napabucasin for non-small cell lung cancer - SWOT analysis
  • Figure 146: Datamonitor Healthcare's drug assessment summary for napabucasin in non-small cell lung cancer
  • Figure 147: Datamonitor Healthcare's drug assessment summary for napabucasin in non-small cell lung cancer
  • Figure 148: Veliparib for non-small cell lung cancer - SWOT analysis
  • Figure 149: Datamonitor Healthcare's drug assessment summary for veliparib in non-small cell lung cancer
  • Figure 150: Datamonitor Healthcare's drug assessment summary for veliparib in non-small cell lung cancer

List of tables

  • Table 1: Non-small cell lung cancer market value in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 2: Non-small cell lung cancer market value in the US, Japan, and five major EU markets, by drug class ($m), 2014-23
  • Table 3: Estimated approval dates of PD-1/PD-L1 inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, 2014-23
  • Table 4: Sales of PD-1/PD-L1 inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
  • Table 5: Sales of EGFR inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
  • Table 6: Sales of ALK inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand ($m), 2014-23
  • Table 7: Summary of drug classes and molecules in Datamonitor Healthcare's non-small cell lung cancer forecast, 2014-23
  • Table 8: Price sources and calculations, by country
  • Table 9: Exchange rates used for calculating prices
  • Table 10: Patent expiry dates for key marketed brands in non-small cell lung cancer in the US, Japan, and five major EU markets, 2014-23
  • Table 11: Estimated launch dates of key pipeline products and marketed brands in NSCLC in the US, Japan, and five major EU markets, 2014-23
  • Table 12: Abemaciclib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 13: Abemaciclib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 14: Abraxane sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 15: Abraxane patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 16: Alecensa sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 17: Alecensa patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 18: Alimta sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 19: Alimta patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 20: Atezolizumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 21: Atezolizumab patient numbers for non-small cell lung cancer in the US, Japan, and five majorEU markets, by country ($m), 2014-23
  • Table 22: Avastin sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 23: Avastin patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 24: Avelumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 25: Avelumab patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 26: AZD9291 sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 27: AZD9291 patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 28: Brigatinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 29: Brigatinib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 30: Cyramza sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 31: Cyramza patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 32: Durvalumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 33: Durvalumab patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 34: Ganetespib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 35: Ganetespib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 36: Gilotrif sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 37: Gilotrif patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 38: Iressa sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 39: Iressa patient numbers for non-small cell lung cancer in the US, Japan, and five major E markets, by country ($m), 2014-23
  • Table 40: Keytruda sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 41: Keytruda patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 42: Necitumumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 43: Necitumumab patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 44: Opdivo sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 45: Opdivo patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 46: Rociletinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 47: Rociletinib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 48: Selumetinib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 49: Selumetinib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 50: Tarceva sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 51: Tarceva patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 52: TG4010 sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 53: TG4010 patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 54: Tremelimumab sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 55: Tremelimumab patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 56: Vargatef sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 57: Vargatef patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 58: Veliparib sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 59: Veliparib patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 60: Xalkori sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 61: Xalkori patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 62: Yervoy sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 63: Yervoy patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 64: Zykadia sales for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 65: Zykadia patient numbers for non-small cell lung cancer in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 66: Medical oncologists, respiratory internists, and respiratory surgeons surveyed for the NSCLC primary research study
  • Table 67: NSCLC five-year survival rates, by stage at diagnosis, 2004-10
  • Table 68: Leading treatments for NSCLC across the US, Japan, and five major EU markets
  • Table 69: Five-year relative survival rates in the US, by lung cancer type and stage at diagnosis, 2004-10
  • Table 70: Cancer registry data sources used
  • Table 71: Data sources used for stage distribution and survival
  • Table 72: Incident cases of lung cancer (all types) in the US, Japan, and five major EU markets, 2013-33
  • Table 73: Incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, 2013-33
  • Table 74: Age-specific incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, by market, 2013
  • Table 75: Sex-specific incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, by market, 2013
  • Table 76: Staging distribution of non-small cell lung cancer incident cases in the US, Japan, and five major EU markets, by market, 2013
  • Table 77: Incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, by stage and market, 2013
  • Table 78: Frequency of common gene mutations in non-small cell lung cancer, 2013
  • Table 79: Incident cases of non-small cell lung cancer in the US, Japan, and five major EU markets, by gene mutation and market, 2013
  • Table 80: Key marketed products for non-small cell lung cancer
  • Table 81: Alecensa drug profile
  • Table 82: Alecensa pivotal trial data in non-small cell lung cancer
  • Table 83: Alecensa ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 84: Alimta drug profile
  • Table 85: Alimta pivotal trial data in non-small cell lung cancer
  • Table 86: Alimta late-phase trial data in non-small cell lung cancer
  • Table 87: Alimta ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 88: Avastin drug profile
  • Table 89: Avastin pivotal trial data in non-small cell lung cancer
  • Table 90: Avastin late-phase trial data in non-small cell lung cancer
  • Table 91: Cyramza drug profile
  • Table 92: Cyramza pivotal trial data in non-small cell lung cancer
  • Table 93: Cyramza ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 94: Gilotrif drug profile
  • Table 95: Gilotrif pivotal trial data in non-small cell lung cancer
  • Table 96: Gilotrif late-phase trial data in non-small cell lung cancer
  • Table 97: Iressa drug profile
  • Table 98: Iressa pivotal trial data in non-small cell lung cancer
  • Table 99: Iressa late-phase trial data in non-small cell lung cancer
  • Table 100: Keytruda drug profile
  • Table 101: Keytruda pivotal trial data in non-small cell lung cancer
  • Table 102: Keytruda ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 103: Opdivo drug profile
  • Table 104: Opdivo pivotal trial data in non-small cell lung cancer
  • Table 105: Opdivo ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 106: Portrazza drug profile
  • Table 107: Portrazza pivotal trial data in non-small cell lung cancer
  • Table 108: Tagrisso drug profile
  • Table 109: Tagrisso pivotal trial data in non-small cell lung cancer
  • Table 110: Tagrisso ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 111: Tarceva drug profile
  • Table 112: Tarceva pivotal trial data in non-small cell lung cancer
  • Table 113: Tarceva late-phase trial data in non-small cell lung cancer
  • Table 114: Tarceva ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 115: Vargatef drug profile
  • Table 116: Vargatef pivotal trial data in non-small cell lung cancer
  • Table 117: Xalkori drug profile
  • Table 118: Xalkori pivotal trial data in non-small cell lung cancer
  • Table 119: Xalkori late-phase trial data in non-small cell lung cancer
  • Table 120: Zykadia drug profile
  • Table 121: Zykadia pivotal trial data in non-small cell lung cancer
  • Table 122: Zykadia ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 123: Late-phase pipeline products in development for non-small cell lung cancer
  • Table 124: Late-stage compounds that were recently discontinued for non-small cell lung cancer
  • Table 125: ASP8273 drug profile
  • Table 126: ASP8273 Phase III trials in non-small cell lung cancer
  • Table 127: ASP8273 early-phase data in non-small cell lung cancer
  • Table 128: Lucanix drug profile
  • Table 129: Lucanix Phase III and Phase II data in non-small cell lung cancer
  • Table 130: Tecentriq drug profile
  • Table 131: Tecentriq Phase III trials in non-small cell lung cancer
  • Table 132: Tecentriq early-phase data in non-sm
Back to Top